Puma Biotech (PBYI) Tops Q3 EPS by 59c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. TLT
10. AMZN

Go back to Puma Biotech (PBYI) Tops Q3 EPS by 59c, Revenues Miss

Puma Biotech (PBYI) Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX

November 5, 2019 5:15 PM EST

Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that its licensing partner in Greater China, CANbridge Pharmaceuticals Inc., has received registration approval from the Department of Health in Hong Kong to market NERLYNX® (neratinib) for the extended adjuvant treatment of adult patients with early stage hormone receptor... More